Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 6/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.49 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.49 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2723833 | 0.85 | GAA (0.68) | GAAALDH1A1TSHRNFKB1TDP1 | |
| SCHEMBL198282 | 0.84 | ALDH1A1 (0.62) | GAAALDH1A1GFERABL1RIN1 | |
| SCHEMBL29626821 | 0.84 | ALDH1A1 (0.62) | GAAALDH1A1GFERABL1RIN1 | |
| SCHEMBL5742684 | 0.84 | EPHX2 (0.49) | GAAMAPTCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL1446362 | 0.84 | ALOX5 (0.50) | KMT2AMEN1 | |
| SCHEMBL17124777 | 0.83 | JAK2 (0.55) | GAAALDH1A1GFERCYP4F2CYP4A11 | |
| SCHEMBL30094581 | 0.81 | GAA (0.53) | GAAALDH1A1GFERCYP4F2CYP4A11 | |
| SCHEMBL3759057 | 0.81 | GAA (0.53) | GAAALDH1A1GFERCYP4F2CYP4A11 | |
| SCHEMBL2094025 | 0.81 | GAA (0.53) | GAAALDH1A1GFERCYP4F2CYP4A11 | |
| SCHEMBL1011093 | 0.81 | GAA (0.73) | GAAALDH1A1GFERHSP90AB1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9371294-B2 | Cycloalkenyl aryl derivatives for CETP inhibitor | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2016-06-21 | — | — | US | disclosed |
| US-9371294-B2 | Cycloalkenyl aryl derivatives for CETP inhibitor | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2016-06-21 | — | — | US | disclosed |
| CN-103269592-B | Cyclic amine substituted oxazolidinone CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-05-11 | — | — | CN | disclosed |
| US-20150119376-A2 | CYCLOALKENYL ARYL DERIVATIVES FOR CETP INHIBITOR | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2015-04-30 | — | — | US | disclosed |
| US-20150119376-A2 | CYCLOALKENYL ARYL DERIVATIVES FOR CETP INHIBITOR | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2015-04-30 | — | — | US | disclosed |
| US-20140031335-A1 | CYCLOALKENYL ARYL DERIVATIVES FOR CETP INHIBITOR | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2014-01-30 | — | — | US | disclosed |
| US-20140031335-A1 | CYCLOALKENYL ARYL DERIVATIVES FOR CETP INHIBITOR | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2014-01-30 | — | — | US | disclosed |
| CN-103269592-A | Cyclic amine substituted oxazolidinone cetp inhibitor | MERCK SHARP & DOHME | 2013-08-28 | — | — | CN | disclosed |
| EP-1971595-A2 | CETP INHIBITORS | Merck & Co., Inc. (US) | 2008-09-24 | — | — | EP | disclosed |
| WO-2007081569-A2 | CETP INHIBITORS | MERCK & CO., INC. (US) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119376-A2 | CYCLOALKENYL ARYL DERIVATIVES FOR CETP INHIBITOR | CETP, MTTP, LCAT | GAA 1008/4885ALDH1A1 2691/4885GFER 3403/4885 |
| US-20140031335-A1 | CYCLOALKENYL ARYL DERIVATIVES FOR CETP INHIBITOR | CETP, MTTP, LCAT | GAA 1008/4885ALDH1A1 2691/4885GFER 3403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.